The Race to Biosimilar Semaglutide: Who’s Ahead and What It Means for Pricing
Executive Summary
Novo Nordisk’s semaglutide composition-of-matter patent expires in the United States in March 2027 (extending to September 2027 with pediatric exclusivity). With $38.7 billion in 2025 revenue at stake, semaglutide is the most valuable patent expiry in pharmaceutical history. At least eight companies are developing biosimilar versions, but the barriers to entry — $500 million capital requirements, 40+ process patents extending to 2034, and unprecedented manufacturing complexity — will limit the field to a handful of viable competitors. Here is the competitive landscape as of mid-2026.
The Contenders
| Company | Status | Manufacturing | Estimated Entry | Strengths |
|---|---|---|---|---|
| Biocon | Phase III | In-house (India) | 2028 | Biosimilar track record; established US distribution |
| Viatris/Mylan | Phase III | CDMO partnership | 2028 | Complex generic expertise; ANDA capability |
| Sandoz | Phase I/III | In-house (Austria) | 2029 | Biosimilar market leader; European strength |
| Teva | Phase I | CDMO | 2030 | Generic distribution infrastructure |
| Hybio/Sinopep | Preclinical/Phase I | In-house (China) | 2029–2030 | Lowest manufacturing cost |
The competitive landscape reveals a tight race among the first three entrants, with Biocon holding a slight lead based on biosimilar experience and integrated manufacturing. However, the timeline is highly sensitive to litigation: Novo Nordisk has filed patent infringement suits against Biocon and Viatris, alleging that their manufacturing processes infringe process patents extending to 2034. If the courts side with Novo Nordisk, biosimilar entry could be delayed until 2032–2034.
Pricing Implications
Biosimilar pricing for peptide drugs does not follow the small-molecule generic pattern of 80–90% discounts. The capital intensity, manufacturing complexity, and regulatory requirements for peptide biosimilars create a natural oligopoly: when there are fewer than 5 competitors, price discounts typically stabilize at 20–40%. The first biosimilar semaglutide is likely to launch at a 25–35% discount to the reference product, with prices declining to a 40–60% discount as additional entrants join. This is consistent with the pricing dynamics observed for other peptide biosimilars (glatiramer acetate, teriparatide) and fundamentally different from small-molecule generic erosion.
Expert Insight: The ANDA vs. 505(b)(2) Question
The regulatory pathway for semaglutide biosimilars is itself contested. Biocon and Viatris are pursuing 351(k) biosimilar applications under the BPCIA, which requires clinical immunogenicity data but provides 12 months of first-mover exclusivity for the first interchangeable designation. Sandoz appears to be pursuing a 505(b)(2) NDA, which relies in part on Novo Nordisk’s clinical data but requires less extensive analytical similarity demonstration. The choice of pathway has enormous commercial implications: a 351(k) interchangeable designation allows pharmacy-level substitution (the holy grail of biosimilar uptake), while a 505(b)(2) NDA does not.
What experienced regulatory strategists know: The FDA has never designated a peptide as interchangeable under the BPCIA. The analytical complexity of demonstrating “no clinically meaningful differences” for a 31-residue lipidated peptide — where each batch contains dozens of structurally related impurities — is unprecedented. The first company to achieve interchangeable designation for a peptide biosimilar will set a precedent that shapes the regulatory pathway for the entire class.
Frequently Asked Questions
When will semaglutide prices actually come down?
Meaningful price competition is unlikely before 2029, when at least two biosimilars are expected to be on the market. Until then, Novo Nordisk retains effective monopoly pricing power, moderated only by competition from tirzepatide (which is priced comparably). The first biosimilar entrant in 2028 will likely price at a modest 25–30% discount, not the deep discount patients and payers hope for.
How will biosimilar semaglutide affect the obesity market?
Lower prices will expand access dramatically — but not immediately. The primary constraint on GLP-1 access today is manufacturing capacity, not price. Until biosimilar entrants add meaningful new manufacturing capacity (2029+), lower list prices will primarily benefit payers through rebate negotiations, not patients through lower out-of-pocket costs. The real access expansion will come when biosimilar manufacturers deploy their lower-cost API to offer net prices 50%+ below the reference product.
Further Reading
Last reviewed: June 2026. Peptide Proof Editorial Team.
